文献速递心脑血管急症消化、代谢与肾脏急症

决策支持干预与急诊科房颤抗凝治疗:O'CAFÉ 阶梯楔形整群随机临床试验

Decision Support Intervention and Anticoagulation for Emergency Department Atrial Fibrillation: The O'CAFÉ Stepped-Wedge Cluster Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-11-04
一句话结论多管齐下的决策支持干预未显著提高急诊科房颤或房扑患者出院时或30天内的抗凝启动率(调整OR 1.33,95%CI 0.75-2.35,P=0.13)。

O'CAFÉ 阶梯楔形整群随机临床试验于2021年7月1日至2023年4月30日在北加州一个整合医疗系统的13个社区医疗中心(9个集群)开展,纳入出院回家的成人急诊房颤或房扑且适合启动抗凝的患者。干预包括医生教育、机构特异性审计反馈和决策支持工具,主要终点为出院时或30天内启动抗凝的复合终点。在1203例适合启动抗凝的患者中,干预组816例中558例(68.4%)启动抗凝,对照组387例中244例(63.0%)启动抗凝,意向性治疗分析显示无统计学显著差异(调整OR 1.33,95%CI 0.75-2.35,P=0.13)。按方案分析中,使用决策支持的患者抗凝启动率显著高于未使用者(75.6% vs 65.8%,P=0.008)。

要点

  • 在1203例适合启动抗凝的急诊房颤或房扑患者中,干预组558/816(68.4%)启动抗凝,对照组244/387(63.0%)启动抗凝,调整OR 1.33(95%CI 0.75-2.35),P=0.13,未达统计学显著。
  • 按方案分析显示,使用决策支持的217例患者中164例(75.6%)启动抗凝,未使用的599例中394例(65.8%)启动抗凝,P=0.008,差异有统计学意义。
  • 干预组出院时启动抗凝428/816(52.5%),30天内启动130/816(15.9%);对照组出院时启动190/387(49.0%),30天内启动54/387(14.0%)。
  • 3388例出院回家的房颤患者中,2185例(64.5%)在急诊就诊前已接受抗凝,仅1203例(35.5%)适合启动抗凝。
  • 决策支持仅被用于217例适合患者(26.6%),使用率偏低可能是干预未显效的原因之一。

适用人群与场景

  • 成人急诊患者,主要诊断为房颤或房扑,适合启动抗凝并出院回家。
  • 来自北加州一个整合医疗系统的13个社区医疗中心(9个集群)。
  • 排除标准未在摘要中明确列出。

处置流程与药物剂量

  • 干预措施包括:医生教育、机构特异性审计和反馈、以及决策支持工具;决策支持工具识别适合患者并推荐共享决策、启动抗凝(如合适)和及时随访。
  • 干预为多管齐下策略,但决策支持的实际使用率仅为26.6%(217/816例适合患者)。

研究设计与关键结果

  • 研究设计:O'CAFÉ 阶梯楔形整群随机临床试验,于2021年7月1日至2023年4月30日在北加州13个社区医疗中心(9个集群)开展,采用1:1交叉设计,集群随机分配至不同日期从对照期(常规护理)交叉至干预期。
  • 样本量:共3388例出院回家的房颤患者,其中2185例(64.5%)在急诊就诊前已接受抗凝,1203例(35.5%)适合启动抗凝。适合启动抗凝的患者中,中位年龄74.0岁(IQR 68.0-82.0),男性618例(51.4%)。
  • 主要终点(意向性治疗分析):干预组816例中558例(68.4%)启动抗凝(出院时428例[52.5%],30天内130例[15.9%]);对照组387例中244例(63.0%)启动抗凝(出院时190例[49.0%],30天内54例[14.0%]);调整OR 1.33(95%CI 0.75-2.35),P=0.13,无统计学显著差异。
  • 次要终点(按方案分析):使用决策支持的217例中164例(75.6%)启动抗凝,未使用的599例中394例(65.8%)启动抗凝,P=0.008,差异有统计学意义。

证据类型、等级与局限

  • 证据类型:阶梯楔形整群随机临床试验(pragmatic, stepped-wedge cluster randomized clinical trial)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该多管齐下干预(医生教育、审计反馈、决策支持)未能显著提高急诊科房颤或房扑患者的抗凝启动率。
  • 决策支持工具的实际使用率较低(26.6%),可能影响干预效果;作者认为在急诊原发性房颤患者中改善卒中预防仍有空间。

指南或共识出处

  • O'CAFÉ 试验,ClinicalTrials.gov 注册号 NCT05009225。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Oral anticoagulation for adults with atrial fibrillation or atrial flutter (AFF) who are at elevated stroke risk reduces the incidence of ischemic stroke but remains underused. Efforts to increase anticoagulation initiation on emergency department (ED) discharge have yielded conflicting results.

OBJECTIVE: To evaluate the effectiveness of a multipronged intervention supporting anticoagulation initiation for eligible adult ED patients.

DESIGN, SETTING, AND PARTICIPANTS: The Clinical Decision Support to Optimize Care of Patients With Atrial Fibrillation or Flutter in the Emergency Department (O'CAFÉ) pragmatic, stepped-wedge cluster randomized clinical trial was conducted from July 1, 2021, through April 30, 2023, at 13 community medical centers (in 9 clusters) of an integrated health system in Northern California. The study included adult ED patients with primary AFF eligible for anticoagulation initiation when discharged home. Clusters were randomly assigned to staggered dates for 1-way crossover from the control phase (usual care) to the intervention phase.

INTERVENTION: Physician education, facility-specific audit and feedback, and access to decision support, which identified eligible patients and recommended shared decision-making, anticoagulation initiation (if suitable), and timely follow-up.

MAIN OUTCOMES AND MEASURES: The main outcome was a composite of anticoagulation on discharge or within 30 days. A primary intention-to-treat analysis (decision support access regardless of use) and a secondary per-protocol analysis (decision support use) were performed. Multivariable analyses adjusted for intervention and exposure months with random effects, accounting for clustering by facility and patient.

RESULTS: A total of 3388 eligible patients with atrial fibrillation were discharged home: 2185 (64.5%) were receiving pre-ED arrival anticoagulation and 1203 (35.5%) were eligible for anticoagulation. Among the 1203 patients with an initiation-eligible encounter, the median age was 74.0 (IQR, 68.0-82.0) years and approximately half (618 [51.4%]) were men. Among the 387 patients with an initiation-eligible control encounter, 244 (63.0%) received anticoagulation (190 [49.0%] at discharge and 54 [14.0%] within 30 days). Among the 816 patients with an initiation-eligible intervention encounter, 558 (68.4%) received anticoagulation (428 [52.5%] on discharge and 130 [15.9%] within 30 days). There was no statistically significant change in initiation of anticoagulation associated with the intervention (adjusted odds ratio, 1.33 [95% CI, 0.75-2.35]; P = .13). Decision support was used for 217 eligible case patients (26.6%) (per protocol) and was associated with a statistically significant change in anticoagulation initiation when compared with 599 patients for whom decision support was not used (164 [75.6%] vs 394 [65.8%]; P = .008).

CONCLUSIONS AND RELEVANCE: In this trial, a multipronged intervention to facilitate thromboprophylaxis among eligible ED patients with AFF did not significantly increase anticoagulation initiation. Opportunities exist to further improve stroke prevention among ED patients with primary AFF.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05009225.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Vinson DR, Warton EM, Durant EJ, et al. Decision Support Intervention and Anticoagulation for Emergency Department Atrial Fibrillation: The O'CAFÉ Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39504024. doi:10.1001/jamanetworkopen.2024.43097

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。